NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$27.16
-1.46 (-5.10%)
Close of Nov 06, 2026 · end-of-day data
ENOV 8-K filings in 2026
Every material Form 8-K Enovis filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Enovis reported third-quarter 2026 net sales of $559 million, up 2% on a reported basis and 5% organic, and net income of $3 million compared with a net loss of $571 million a year earlier. The company raised its full-year adjusted EBITDA and adjusted EPS guidance, narrowed its revenue guidance, and approved a new $200 million share repurchase authorization.
Q3 net sales of $559 million, up 2% reported and 5% organic; adjusted EPS of $0.88 versus $0.75 a year earlier
2026 adjusted EBITDA guidance raised to $428-438 million from $425-435 million
2026 adjusted EPS guidance raised to $3.58-3.79 from $3.52-3.73; revenue guidance narrowed to $2.32-2.35 billion from $2.31-2.37 billion
New $200 million share repurchase authorization replaces the existing $100 million authorization
Enovis reported second-quarter 2026 net sales of $583 million, up 3% on a reported basis and 5% organically, and a net loss of $1 million, or $0.02 per share, compared with a net loss of $36.5 million a year earlier. The company reaffirmed its full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS and free cash flow conversion.
Q2 net sales of $583 million, up 3% reported and 5% organic; Recon sales up 8% reported, P&R down (1)% reported
Q2 net loss of $1 million ($0.02 per share) versus $36.5 million loss in Q2 2025; adjusted EBITDA of $104 million, or 17.9% of sales
Adjusted EPS of $0.90 for Q2 2026; full-year guidance reaffirmed: revenue $2.31-2.37 billion, adjusted EBITDA $425-435 million, adjusted EPS $3.52-3.73
Conference call scheduled for 8:30 a.m. Eastern on August 6, 2026
At its May 19, 2026 annual meeting, Enovis stockholders approved an amendment to the 2020 Omnibus Incentive Plan that authorizes 3,650,000 additional common shares and raises the annual compensation limit for outside directors from $350,000 to $750,000. Stockholders also elected ten directors, ratified Ernst & Young LLP as auditor for 2026, and approved executive compensation in a non-binding vote.
The plan amendment authorizes 3,650,000 additional shares of common stock for issuance under the 2020 Omnibus Incentive Plan.
The annual cap on equity and cash compensation for outside directors rises from $350,000 to $750,000, with up to 200% allowed in the year of a new election or appointment.
The plan amendment received 50,391,554 votes for and 1,295,073 against.
Named executive officer compensation was approved by 49,531,111 votes for and 2,175,335 against.
Enovis reported first-quarter 2026 net sales of $589 million, up 5% on a reported basis and 3% organic, and a net loss of $8 million, or $0.15 per share, compared with a net loss of $55.7 million a year earlier. The company reaffirmed its full-year 2026 revenue, adjusted EBITDA, adjusted EPS and free cash flow conversion guidance, which matters to shareholders because it signals no change to its outlook.
Net sales $589 million, up 5% reported and 3% organic; Reconstructive sales up 11% reported
Net loss $8 million ($0.15 per share) versus a $55.7 million net loss in the prior-year quarter
Adjusted EBITDA $104 million (17.6% of sales) and adjusted EPS $0.89, versus $0.65 a year earlier
Enovis reported full-year 2025 net sales of $2.2 billion, up 7% on a reported basis, but a $1.05 billion non-cash goodwill impairment pushed its net loss from continuing operations to $1,182 million. The company also gave 2026 guidance of $2.31-2.37 billion in revenue, $425-435 million in adjusted EBITDA and $3.52-3.73 in adjusted earnings per share, which shareholders can compare with the 2025 results.
Full-year 2025 net sales of $2.2 billion grew 7% reported and 6% organically; Recon rose 10% and Prevention & Recovery rose 4%.
Full-year 2025 net loss from continuing operations was $1,182 million, including a $1,050 million non-cash goodwill impairment charge.
Full-year 2025 adjusted earnings per diluted share were $3.30, compared with $2.84 in 2024; GAAP loss was $20.72 per share.
2026 outlook: revenue of $2.31-2.37 billion, adjusted EBITDA of $425-435 million and adjusted EPS of $3.52 to $3.73.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Enovis filing is on SEC EDGAR ↗. 8-K briefs of other companies →